Evidence map›Paper›PMID 25521684›Full record

ArticleNature immunology2015

The immunology of asthma.

Bart N Lambrecht, Hamida Hammad

Abstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 822 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
822citing papers in PubMed, 7 pooled it
43.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

822 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,613 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pharmacological insights intoFrontiers in pharmacology · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

762 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Bart N Lambrecht1] VIB Inflammation Research Center, Ghent University, Ghent, Belgium. [2] Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium. [3] Department of Pulmonary Medicine, Erasmus MC, Rotterdam, the Netherlands.
Hamida Hammad1] VIB Inflammation Research Center, Ghent University, Ghent, Belgium. [2] Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium.
Ghent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is a common disease that affects 300 million people worldwide. Given the large number of eosinophils in the airways of people with mild asthma, and verified by data from murine models, asthma was long considered the hallmark T helper type 2 (TH2) disease of the airways. It is now known that some asthmatic inflammation is neutrophilic, controlled by the TH17 subset of helper T cells, and that some eosinophilic inflammation is controlled by type 2 innate lymphoid cells (ILC2 cells) acting together with basophils. Here we discuss results from in-depth molecular studies of mouse models in light of the results from the first clinical trials targeting key cytokines in humans and describe the extraordinary heterogeneity of asthma.

Indexed as

AnimalsAsthmaClinical Trials as TopicDisease Models, AnimalEosinophilsHumansTh17 CellsTh2 Cells

Identifiers

PMID25521684
OpenAlexW2082624887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.